Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Markets Earnings Roundup: Novartis (Part 3)

This article was originally published in PharmAsia News

Executive Summary

Novartis had a busy second quarter with Diovan in the news and a major deal with GSK that portends an evolving focus in emerging markets.

You may also be interested in...



Novartis Reveals Pharma Leadership Changes Amid Business Transition

Novartis announced Vas Narasimhan will be global head of development for Novartis’ pharma unit, and Rainer Boehm will be chief commercial officer of general medicines.

List Ahead For Southeast Asia Pharma In 2015

PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.

Southeast Asia 2014: Distribution, Manufacturing To The Fore

Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.

Topics

Related Companies

UsernamePublicRestriction

Register

SC087684

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel